Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.83 - $3.94 $134,708 - $187,544
47,600 New
47,600 $174,000
Q1 2024

May 15, 2024

BUY
$2.03 - $6.59 $86,071 - $279,416
42,400 New
42,400 $180,000

Others Institutions Holding PYXS

About Pyxis Oncology, Inc.


  • Ticker PYXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,096,400
  • Market Cap $58.6M
  • Description
  • Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...
More about PYXS
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.